{
  "abstract": "Background: Although papillary thyroid carcinoma (PTC) has a relatively good prognosis, it is also prone to recurrence and metastasis. Cyclin-dependent kinase inhibitor 2 A (CDKN2A) can affect tumor progression by regulating ferroptosis, but its role in PTC remains unclear.\n\nMaterials and methods: The expression of CDKN2A, p14, p16, GPX4, and TFRC in PTC was assessed by qPCR, western blotting, and immunohistochemistry, and their clinical correlations were analyzed. In TPC-1 and BCPAP cells, CDKN2A/p14/p16 expression was modulated, followed by evaluation of ferroptosis-related changes using GPX4, TFRC, Fe2⁺, ROS, GSH, C11-BODIPY lipid peroxidation, and transmission electron microscopy. Cell proliferation and migration were assessed by CCK-8, colony formation, wound-healing, and Transwell assays. The p53/SLC7A11/GPX4 pathway was examined, and rescue experiments were conducted using p53 agonist and inhibitor. In vivo tumorigenicity was evaluated using a nude mouse xenograft model.\n\nResults: CDKN2A was upregulated in PTC and associated with advanced clinicopathological features and lipid metabolism, but was not an independent prognostic factor. Silencing CDKN2A (p14, p16) induced ferroptosis, inhibiting tumor progression; in contrast, overexpression of p14 and p16 inhibited ferroptosis and promoted malignant phenotypes, with p16 playing a predominant role. Moreover, overexpression of p16 could partially resist the induction of ferroptosis by RSL3. Mechanistically, p53 agonist/inhibitor rescue experiments suggested p16 affected p53/SLC7A11/GPX4 pathway. In vivo, p16 overexpression increased tumor growth by inhibiting ferroptosis.\n\nConclusion: CDKN2A promotes PTC progression by suppressing ferroptosis via indirect regulation of p53/SLC7A11/GPX4 pathway, primarily through the p16 isoform. Targeted inhibition of p16 isoform is a potential therapeutic strategy for PTC.",
  "abstract_shown": true,
  "affiliations": [
    "Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China",
    "Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China",
    "Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China",
    "Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China",
    "Department of Neurology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China",
    "Yantai Municipal Key Medical and Health Laboratory of Yantai Yuhuangding Hospital (Interdisciplinary Brain Science and Geriatric Health Laboratory), Qingdao University, Yantai, China"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0,
        1,
        2,
        3
      ],
      "name": "Yao Wang"
    },
    {
      "affs": [
        0,
        1,
        2,
        3
      ],
      "name": "Ya-Kui Mou"
    },
    {
      "affs": [
        0,
        1,
        2,
        3
      ],
      "name": "Ting Yang"
    },
    {
      "affs": [
        0,
        1,
        2,
        3
      ],
      "name": "Han-Rui Wang"
    },
    {
      "affs": [
        0,
        1,
        2,
        3
      ],
      "name": "Xiao-Yu Song"
    },
    {
      "affs": [
        0,
        1,
        2,
        3
      ],
      "name": "Wan-Chen Liu"
    },
    {
      "affs": [
        0,
        1,
        2,
        3
      ],
      "name": "Hui Shen"
    },
    {
      "affs": [
        0,
        4,
        5
      ],
      "name": "Chao Ren"
    },
    {
      "affs": [
        0,
        1,
        2,
        3
      ],
      "name": "Xi-Cheng Song",
      "orcid": "0000-0002-9789-1318"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/ce8y87ehzf1vh.bib",
  "cited_by": 0,
  "doi": "10.1080/15384047.2026.2760033",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13757698/",
  "id": "ce8y87ehzf1vh",
  "issns": [
    "1538-4047",
    "1555-8576"
  ],
  "landing_url": "https://doi.org/10.1080/15384047.2026.2760033",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research Article"
    ],
    [
      "openalex",
      "1306|Ferroptosis and cancer prognosis"
    ]
  ],
  "openalex": "W7225827357",
  "pdf_url": "https://www.tandfonline.com/doi/pdf/10.1080/15384047.2026.2760033?needAccess=true",
  "pmcid": "PMC13757698",
  "pmid": "43013616",
  "published": "2026-11-11",
  "publisher": "Taylor & Francis",
  "ris": "https://research.draconitic.com/paper/ce8y87ehzf1vh.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:23:17Z",
      "native_id": "PMC13757698",
      "source": "pmc",
      "url": "https://doi.org/10.1080/15384047.2026.2760033"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:1306|Ferroptosis and cancer prognosis",
      "subfield": "oncology"
    }
  ],
  "title": "The p16 isoform of CDKN2A inhibits ferroptosis to promote the progression of papillary thyroid carcinoma by influencing the p53/SLC7A11/GPX4 pathway",
  "title_text": "The p16 isoform of CDKN2A inhibits ferroptosis to promote the progression of papillary thyroid carcinoma by influencing the p53/SLC7A11/GPX4 pathway",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:23:17Z",
  "url": "https://research.draconitic.com/paper/ce8y87ehzf1vh",
  "venue": "Cancer Biology & Therapy",
  "versions": []
}